ARCA biopharma Company Profile (NASDAQ:ABIO)

About ARCA biopharma (NASDAQ:ABIO)

ARCA biopharma logoARCA biopharma, Inc. (ARCA) is a biopharmaceutical company. The Company is principally focused on developing genetically-targeted therapies for cardiovascular diseases. The Company's lead product candidate is Gencaro (bucindolol hydrochloride), a beta-blocker and mild vasodilator that the Company is evaluating in a clinical trial for the treatment of atrial fibrillation (AF) in patients with heart failure with reduced left ventricular ejection fraction (HFREF). Gencaro is considered part of the beta-blocker class of compounds because of its property of blocking both beta-1 and beta-2, receptors in the heart. The blocking of these receptors prevents the receptor from binding with other molecules, primarily the neurotransmitter norepinephrine (NE), which activate these receptors. The Company is conducting a Phase IIB/III clinical trial of Gencaro, known as GENETIC-AF.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Biopharmaceuticals
  • Sub-Industry: N/A
  • Symbol: NASDAQ:ABIO
  • CUSIP: N/A
  • Web:
  • Market Cap: $18.16 million
  • Outstanding Shares: 11,750,000
Average Prices:
  • 50 Day Moving Avg: $1.28
  • 200 Day Moving Avg: $1.97
  • 52 Week Range: $1.05 - $3.00
  • Trailing P/E Ratio: N/A
  • P/E Growth: 0.00
Sales & Book Value:
  • Annual Revenue: N/A
  • Price / Sales: N/A
  • Book Value: $1.46 per share
  • Price / Book: 0.89
  • EBITDA: ($18,560,000.00)
  • Return on Equity: -92.16%
  • Return on Assets: -82.33%
  • Current Ratio: 6.63%
  • Quick Ratio: 6.63%
  • Average Volume: 163,842 shs.
  • Beta: 1.98
  • Short Ratio: 0.48

Frequently Asked Questions for ARCA biopharma (NASDAQ:ABIO)

What is ARCA biopharma's stock symbol?

ARCA biopharma trades on the NASDAQ under the ticker symbol "ABIO."

How were ARCA biopharma's earnings last quarter?

ARCA biopharma, Inc. (NASDAQ:ABIO) posted its quarterly earnings results on Thursday, August, 3rd. The company reported ($0.59) earnings per share for the quarter. View ARCA biopharma's Earnings History.

When will ARCA biopharma make its next earnings announcement?

ARCA biopharma is scheduled to release their next quarterly earnings announcement on Monday, November, 13th 2017. View Earnings Estimates for ARCA biopharma.

Who are some of ARCA biopharma's key competitors?

Who are ARCA biopharma's key executives?

ARCA biopharma's management team includes the folowing people:

  • Robert E. Conway, Chairman of the Board
  • Michael R. Bristow M.D., Ph.D., President, Chief Executive Officer, Director
  • Thomas A. Keuer, Chief Operating Officer
  • Christopher David Ozeroff, Senior Vice President, General Counsel, Secretary
  • Brian L. Selby CPA, Chief Accounting Officer, Principal Accounting Officer, Vice President - Finance
  • Linda S. Grais M.D., Lead Independent Director
  • Anders D. Hove M.D., Director
  • Daniel J. Mitchell, Director
  • Raymond L. Woosley M.D., Ph.D., Director

How do I buy ARCA biopharma stock?

Shares of ARCA biopharma can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ARCA biopharma's stock price today?

One share of ARCA biopharma stock can currently be purchased for approximately $1.30.

MarketBeat Community Rating for ARCA biopharma (NASDAQ ABIO)
Community Ranking:  1.9 out of 5 (star)
Outperform Votes:  25 (Vote Outperform)
Underperform Votes:  42 (Vote Underperform)
Total Votes:  67
MarketBeat's community ratings are surveys of what our community members think about ARCA biopharma and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Consensus Ratings for ARCA biopharma (NASDAQ:ABIO) (How are Consensus Ratings Calculated?)
Ratings Breakdown: No ratings tracked in the last 12 months.
Consensus Rating:N/A (Score: NaN)
Consensus Price Target: N/A
Consensus Price Target History for ARCA biopharma (NASDAQ:ABIO)
Price Target History for ARCA biopharma (NASDAQ:ABIO)
Analysts' Ratings History for ARCA biopharma (NASDAQ:ABIO)
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
2/23/2016Royal Bank Of CanadaReiterated RatingSector Perform$5.00 -> $4.00N/AView Rating Details
2/23/2016Cowen and CompanyReiterated RatingMarket Perform$5.50 -> $4.00N/AView Rating Details
(Data available from 10/20/2015 forward)


Earnings History for ARCA biopharma (NASDAQ:ABIO)
Earnings by Quarter for ARCA biopharma (NASDAQ:ABIO)
Earnings History by Quarter for ARCA biopharma (NASDAQ ABIO)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/13/2017N/AView Earnings Details
8/3/2017Q2 2017($0.59)ViewN/AView Earnings Details
5/15/2017Q1 2017($0.48)ViewN/AView Earnings Details
11/14/2016Q3 2016($0.51)ViewN/AView Earnings Details
8/9/2016Q216($0.43)ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for ARCA biopharma (NASDAQ:ABIO)

No earnings estimates for this company have been tracked by


Dividend History for ARCA biopharma (NASDAQ:ABIO)
No dividend announcements for this company have been tracked by

Insider Trades

Insider Trading and Institutional Ownership History for ARCA biopharma (NASDAQ:ABIO)
Insider Ownership Percentage: 3.75%
Institutional Ownership Percentage: 39.07%
Insider Trades by Quarter for ARCA biopharma (NASDAQ:ABIO)
Institutional Ownership by Quarter for ARCA biopharma (NASDAQ:ABIO)
Insider Trades by Quarter for ARCA biopharma (NASDAQ:ABIO)
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
7/14/2017Robert E ConwayChairmanBuy10,000$2.49$24,900.00View SEC Filing  
5/2/2017Daniel J MitchellDirectorBuy11,000$2.71$29,810.00View SEC Filing  
4/4/2017Christopher David OzeroffVPSell418$2.41$1,007.38View SEC Filing  
4/4/2017Michael R. BristowInsiderSell720$2.41$1,735.20View SEC Filing  
4/4/2017Thomas A. KeuerCOOSell390$2.41$939.90View SEC Filing  
4/3/2017Brian L. SelbyVPSell1,114$2.46$2,740.44View SEC Filing  
3/24/2017Robert E ConwayDirectorBuy25,000$2.59$64,750.00View SEC Filing  
2/28/2017Michael R. BristowInsiderSell763$2.61$1,991.43View SEC Filing  
2/28/2017Thomas A. KeuerCOOSell465$2.61$1,213.65View SEC Filing  
10/18/2016Thomas A. KeuerCOOSell483$2.45$1,183.35View SEC Filing  
9/20/2016Christopher David OzeroffVPSell1,185$2.89$3,424.65View SEC Filing  
9/20/2016Michael R. BristowInsiderSell1,972$2.89$5,699.08View SEC Filing  
9/20/2016Thomas A. KeuerCOOSell714$2.89$2,063.46View SEC Filing  
9/19/2016Brian L. SelbyVPSell476$2.91$1,385.16View SEC Filing  
4/5/2016Christopher David OzeroffVPSell366$3.52$1,288.32View SEC Filing  
4/5/2016Michael R BristowInsiderSell724$3.52$2,548.48View SEC Filing  
4/5/2016Thomas A KeuerCOOSell384$3.52$1,351.68View SEC Filing  
4/4/2016Brian L SelbyVPSell1,114$3.52$3,921.28View SEC Filing  
3/1/2016Christopher David OzeroffVPSell458$3.51$1,607.58View SEC Filing  
3/1/2016Michael R. BristowInsiderSell752$3.50$2,632.00View SEC Filing  
3/1/2016Thomas A. KeuerCOOSell457$3.53$1,613.21View SEC Filing  
9/18/2015Christopher David OzeroffVPSell1,129$6.32$7,135.28View SEC Filing  
3/2/2015Brian L SelbyVPSell1,125$0.71$798.75View SEC Filing  
3/2/2015Michael R BristowInsiderSell5,446$0.71$3,866.66View SEC Filing  
1/16/2015Riley MccormackMajor ShareholderSell350,000$0.76$266,000.00View SEC Filing  
1/7/2015Riley MccormackMajor ShareholderSell550,000$0.92$506,000.00View SEC Filing  
9/18/2014Michael R BristowCEOSell13,853$1.30$18,008.90View SEC Filing  
9/18/2014Patrick M WheelerCFOSell8,246$1.31$10,802.26View SEC Filing  
2/4/2014Riley MccormackMajor ShareholderBuy1,000,000$1.70$1,700,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Headline Trends for ARCA biopharma (NASDAQ:ABIO)
Latest Headlines for ARCA biopharma (NASDAQ:ABIO)
DateHeadline logoARCA biopharma (ABIO) Presents At The Sidoti & Company Fall 2017 Convention - Slideshow - September 29 at 3:05 PM logoARCA biopharma to Present at the Sidoti & Company Fall 2017 Conference - September 21 at 3:30 PM logoArca Biopharma (ABIO) Reports Completion of Enrollment for GENETIC-AF Phase 2B Clinical Trial - August 16 at 8:23 PM logoARCA biopharma Announces Completion of Enrollment for GENETIC-AF Phase 2B Clinical Trial - August 16 at 3:21 PM logoGLPG's FLORA Blooms, DVAX, ESPR Price Offering, SGMO Abuzz, HRTX On Track - August 10 at 9:48 PM logoBRIEF-ARCA Biopharma to share top-line results in Q1 next year for GENETIC-AF trial - August 10 at 1:24 AM logoARCA biopharma Announces GENETIC-AF Data and Safety Monitoring Board Recommendation to Complete Phase 2B GENETIC-AF Clinical Trial Based on Efficacy and Safety Data in Phase 2B Interim Analysis - August 9 at 8:23 PM logoARCA biopharma, Inc. (NASDAQ:ABIO) Issues Quarterly Earnings Results - August 5 at 12:56 PM logoARCA biopharma Announces Second Quarter 2017 Financial Results and Provides Business Update - August 3 at 8:37 PM logoARCA biopharma, Inc. (NASDAQ:ABIO) Scheduled to Post Earnings on Monday - July 31 at 8:01 AM logoARCA biopharma, Inc. (ABIO) Chairman Buys $24,900.00 in Stock - July 17 at 7:36 PM logoBRIEF-ARCA Biopharma Q1 loss per share $0.48 - May 15 at 3:15 PM
News IconBRIEF-Arca Biopharma Inc files for mixed shelf of up to $75 mln - April 27 at 1:26 AM logoFDA Nod For Parkinson's Drug, ABIO Awaits Data In Q3, Busy Year Ahead For VKTX - March 22 at 3:17 PM logoARCA biopharma Announces Fiscal Year 2016 Financial Results and Provides Business Update - March 21 at 8:22 PM logoNOVN Moves Ahead, PTCT Finally Achieves It, TGTX Gets GENUINE Reaction - March 7 at 3:15 PM logoARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers - March 1 at 8:16 PM logoAnders Hove, M.D. (Photo: Business Wire) - February 21 at 3:32 PM logoARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Financial Statements and Exhibits - February 21 at 3:32 PM logoARCA BIOPHARMA, INC. Files SEC form 8-K, Entry into a Material Definitive Agreement, Financial Statements and Exhibit - January 11 at 8:17 PM logoARCA biopharma Announces Third Quarter 2016 Financial Results and Provides Business Update - November 14 at 8:55 PM logoBRIEF-Arca Biopharma Q3 loss per share $0.51 - November 14 at 8:55 PM logoDr. Michael R. Bristow, President And CEO, ARCA Biopharma, Inc. - October 7 at 8:02 AM logoEARS Faces The Music, ABIO On Track, TEVA Gets EU Nod For Asthma Drug - August 19 at 11:29 AM logoBRIEF-Arca says 100th patient randomized into the genetic-AF phase 2b/3 clinical trial - August 18 at 3:15 PM logoForm 4 ARCA biopharma, Inc. For: Jun 09 Filed by: Selby Brian L. - June 15 at 3:16 PM logoARCA BIOPHARMA, INC. Files SEC form 8-K, Change in Directors or Principal Officers, Submission of Matters to a Vote o - June 13 at 5:01 PM logoARCA biopharma Announces First Quarter 2016 Financial Results and Provides Business Update - Business Wire (press release) - May 12 at 9:47 AM logoARCA BIOPHARMA, INC. Files SEC form 10-Q, Quarterly Report - May 11 at 4:49 PM logoARCA BIOPHARMA, INC. Files SEC form 8-K, Other Events, Financial Statements and Exhibits - April 18 at 4:31 PM logoARCA biopharma Announces 75th Patient Enrolled in GENETIC-AF Phase 2B/3 Clinical Trial - Business Wire (press release) - April 18 at 10:27 AM logoARCA BIOPHARMA, INC. Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhi - March 17 at 4:44 PM



ARCA biopharma (ABIO) Chart for Friday, October, 20, 2017

This page was last updated on 10/20/2017 by Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.